Amgen reports Q3 2026 revenue up 8%, EPS rises 19%, driven by strong product sales and pipeline progress.

Amgen announced an 8% increase in total revenues to $10.4 billion for Q3 2026, with GAAP EPS rising 19% to $7.08, driven by volume growth across 17 products showing double-digit sales increases. The company highlighted strong commercial performance, clinical advances, and a promising late-stage pipeline, reinforcing confidence in sustained growth. Free cash flow was $3.7 billion, slightly down from last year due to working capital changes. Amgen also provided updates on several late-stage clinical trials and expects full-year 2026 revenues between $38.9 billion and $39.7 billion.

As of Nov 04, 2026 04:11 WIB, Amgen (AMGN) shares are trading at USD 455.00 on Pluang, down 2.25% for the day with a market cap of $251.64 billion. Despite the recent dip, investor interest remains strong with 68% of Pluang orders buying the stock. The company’s dividend yield stands at 2.17%, reflecting steady income potential for shareholders.